Daily Archives: April 14, 2008

McDonald’s (MCD): Being Open 24/7 Key To Sucess

Try to get a Starbucks (NASDAQ: SBUX) at 3 AM. No such luck. But, according to data given to us by McDonald’s (NYSE: MCD), more than 30% of its 13,700 US stores are up 24 hours, seven days a week. Over 50% are open 24 hours at least one day a week.

The practice is not limited to the US. Last year, the number of McDonald’s open around the clock more than doubled in China and rose 27% in Australia.

The world’s largest fast-food chain attributes a great deal of its recent same-store sales growth to morning menus and premium coffee. For many customers, breakfast is not at 8 AM. A lot of people have to be up and out closer to 5 AM due to having jobs which start early or long commutes.

McDonald’s has learned something which would benefit many retail businesses. Being open 24 hours is not all that expensive, in most cases.

At a company like McDonald’s, the largest fixed costs are already in place. Those include real estate, the cost of food, kitchen equipment, and marketing. At a store which would close at 10 PM and open at 6 AM, it takes one more shift of three or four people to operate overnight. Assuming four people at $12 an hour, the total personnel cost is less than $400. Add some cost for the price of utilities and the cost of the food sold and the total expense is probably about $1,000.

Fifty people coming by for $20 meals and the cost of the extra eight hours is paid. McDonald’s in undoubtedly careful about only keeping high traffic stores working overnight, so the profits could be really substantial.

Aside from the money made during the overnight shift, the longer hours bring something that money can’t buy. Customers who get to pick-up something to eat at a McDonald’s in the middle of the night when nothing else is open are probably much more likely to come back during "regular" hours. Convenience can build brand loyalty and McDonald’s can’t put a price on that.

Douglas A. McIntyre

The 52-Week Low Club (CRS)(CC)(FHN)(HBAN)(FITB)

Carpenter Technology (CRS) Company only manages to hit low end of guidance. Drops to $48.10 from 52-week high of $79.66.

Blockbuster (BBI) Bid for Circuit City (CC) sends investors running for the exits. Down to $2.52 from 52-week high of $6.69.

First Horizon Natl Corp (FHN) Poor earnings out of Wachovia (WB) tearing other shares down. Sells off to $11.60 from 52-week high of $41.46.

Huntington Bancshares (HBAN) Another victim of bank sell-off. Falls to $$8.96 from 52-week high of $22.96.

Fifth Third Bancorp (FITB) Bank. Down to $18.96 from 52-week high of $43.32.

Douglas A. McIntyre

Banks And Brokerages May Have Large Earnings Misses, Stocks Could Fall 20%

Early indicators from companies like Wachovia (NYSE: WB) and General Electric (NYSE: GE) show that the last half of March may have been tougher on banks earnings than Wall St. expects. Bloomberg recently reported that Citigroup (NYSE: C), JP Morgan (NYSE: JPM), and Wells Fargo (NYSE: WFC) could all miss consensus estimates. But, by how much?

A look at the spread of Q1 estimates gives some hint about how far off actual numbers could be compared with investor expectations. At Citigroup, among fifteen analysts polled by First Call the average EPS estimate is a loss of $.95. But, the lowest estimate is a loss of $2.24. At JP Morgan, the average figure from fourteen analysts is $.66, but the worst case is a loss of $.11. For Wells Fargo, twenty-three analysts have an average forecast of Q1 EPS at $.57, but the low number is $.45.

The huge discrepancy among the numbers should be troubling to shareholders because recent information would argue that share prices for most banks and brokerages may still be way too high.

At brokerage firms, there is also a very wide spread among analysts who have earnings estimates for the quarter. The consensus among sixteen analysts following Merrill Lynch (NYSE: MER) is that EPS for Q1 will be a loss of $1.90. But, the worst forecast is for $3. Lehman (NYSE: LEH) is expected to make $1.07, but the low end of estimates is $.43. Morgan Stanley (NYSE: MS) expectations are for EPS of $1.34, but the worst forecast is $.79.

What would substantial misses do to share prices? It would almost certainly put stocks in the sector below their 52-week lows. A look at most stocks in the sector shows that number is about 20% below where they trade now.

Unforecast bad news took GE down 13%. For companies perceived to be in a much weaker set of circumstances, the drop is going to be worse.

Douglas A. McIntyre

What Benefit For Google (GOOG): YouTube Traffic Up, Overall Visits To Video Sites Down

Google’s (GOOG) YouTube had a 78% market share among video websites in March, up from 55% a year ago. Most other sites lost share over the period and overall video category visits were down 7%.

Ranking as No.2 among video sites was News Corp’s (NWS) MySpace which had a share drop from almost 18% in March 2007 to 9% last month. Hulu, the new video site set up by several major media companies, came in at No. 22, according to Hitwise.

The report raises two critical issues. The first is why total visits to video sites are dropping?  Perhaps the novelty of these properties has worn off or the lack of quality content at most sites is not holding visitors..

Also at issue is whether any of these websites can ever make money. YouTube does not appear to bring in any significant revenue for Google. When the search company announced its earnings for Q1, the market may be able to determine if that is still correct. 

A year ago, video was "the next big thing" for making money from the internet. Now, it is no better off than another huge loser–social networking.

Douglas A. McIntyre

Biotech Busine$$ Daily (ALKS, CADX, CVTX, MNKD, GNBT, PPHM)

Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder chronic relapse. The drug was already approved for treatment of schizophrenia in 2003. Shares of Alkermes are down to by $0.17 to $10.94 in mid-day trading on a 52-week range of $10.32 to $18.78.

Cadence Pharmaceuticals Inc. (NASDAQ: CADX) up over 8% today on no new developments to $6.74 off a 52-week range of $4.84 to $20.67. Cadence Pharmaceuticals is a development stage biopharmaceutical company with two products in Phase III testing, Acetavance and Omigard.

CV Therapeutics (NASDAQ: CVTX) down today despite FDA approval for its coronary artery treatment, Lexiscan, granted last Friday. The drug is injected into patients during heart tests that cannot exercise to increase blood flow in their arteries. The drug will be marketed by OTC company Astellas Pharma US Inc. and will pay CV Therapeutics $12 million now that drug has been approved. CV Therapeutics is down over 5% to $7.57 on a 52-week range of $5.41 to $13.74.

Mannkind Corp. (NASDSQ: MNKD) still slipping today on Pfizer’s insulin scare earlier this month. Pfizer markets an inhaled insulin product, Exubera, that recently studies showed it be connected with lung cancer in its users. Despite the failings of Pfizer’s inhaled insulin product and other developers of similar treatments (including Alkermes above), Mannkind intends to continue developing its similar product, Technosphere. Shares are down almost 7% to $2.33 today on a 52-week range of $2.15 to $15.65. Pfizer (NYSE: PFE) up marginally today to $20.53 on a 52-week range of $20.19 to $27.73.

Generex Biotechnology Corp. (NASDAQ: GNBT) could benefit from Pfizer’s and Mannkind’s struggles with inhaled insulin treatments. Generex’s product Oral-lyn is viewed as a competing oral insulin product that is safe and effective. Shares are up over 2% to $1.18 today on a 52-week range of $0.81 to $2.14.

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) down almost 11% today after they announced that the pre-clinical study of their anti-PS Vascular Targeting Antibodies showed a broad range of potential for cancer treatment at the American Association of Cancer Research annual meeting. Shares are down to $0.44 on a 52-week range of $0.35 to $1.40.

Rachel Lopez
April 14, 2008

Invesco Launches Active Managed ETF’s (IVZ, PQY, PQZ, PMA, PLK)

Invesco (NYSE: IVZ) PowerShares has launched its first actively-managed ETF on the NYSE Arca Friday. These 4 PowerShares ETFs include 3 first-in-kind equity exchange-funds and one actively-managed fixed income ETF.

The PowerShares Active Alpha Q Fund (NYSE Arca: PQY) and the PowerShares- Active Alpha Multi-Cap Fund (NYSE Arca: PQZ) will be managed by Invesco while the PowerShares- Active Mega-Cap Portfolio (NYSE Arca: PMA) and PowerShares- Active Low Duration Portfolio (NYSE Arca: PLK) will be advised by AER Advisors.

Actively-managed ETF’s are a very recent development, and act more like hedge funds than anything.  Bear Stearns launched the first fixed income EFT (NYSE: YYY) that is actively-managed in March of this year. Previously, ETF’s were almost always tied to an index.

The Alpha Q fund and the Alpha Multi-Cap Funds are the only two to trade so far, with Alpha Q down by less than 1% and Alpha Multi-cap up by less than 1% in early morning trading.

Rachel Lopez
April 14, 2008

ETF Launch: NETS DAX Index Fund (DAX, NTRS)

The American Stock Exchange has launched an ETF called the NETS DAX Index Fund by Northern Trust Global Investments, an arm of Northern Trust Corp. (NASDAQ: NTRS) today. The exchange traded fund will track the German equity market and will be composed of the 30 largest and most active companies on the Frankfurt Stock Exchange. The specialist for the DAX is Susquehanna Investment Group, and this is now listed as NETS DAX INDEX FUND (AMEX: DAX). 

This is the third Northern Trust international based index to trade on the Amex, with the first two being tied to UK and Australia, launched April 9. Around April 16, three more internationally indexed ETFs will begin trading in Hong Kong, Japan, and France.

The NETS DAX hasn’t moved much today, sitting back at the opening price of $24.60 in early trading on extremely thin volume of 400 shares. Northern Trust Corp. is down $1.22 to $66.00 today.

Rachel Lopez
April 14, 2008

Yahoo!’s (YHOO) Huge Advantage: Time Spent On Site

One of the factors lost in the debate over the value of Yahoo! (NASDAQ: YHOO) is the amount of time that consumers spend on the site. For advertisers, especially those running display ads, the hours that users spend per month could be critical to the value of the dollars that they invest to spread their messages.

According to Nielsen numbers for March, the average time spent on Yahoo! was 3 hours and 12 minutes. The figure for Google (NASDAQ: GOOG) was only 1 hour and 15 minutes. For MSN, the number was 2 hours and 13 minutes and for AOL the figure was four hours.

The numbers allow marketers to calculate a 24/7 Wall St. "Advertising Audience Power Rating" based on time spent multiplied by total unique visitors.

Google’s rating would be 149. Yahoo!’s would be much higher at 367. MSN would weigh in at 213, and AOL’s would be 360.

If consumer loyalty can be measured in time spent, Yahoo! and AOL may be more valuable than they seem at first  blush.

Douglas A. McIntyre

IPO FILING: Codexis (CDXS)

Codexis, a biocatalyst developer, submitted an SEC filing Friday evening to come public via an IPO. The offering shows a total proposed maximum price of $100 million, although this amount is for filing purposes only. They intend to trade on the Nasdaq Global Market under the ticker “CDXS.”

The underwriters for the IPO are listed as Credit Suisse, Goldman Sachs and Co., Piper Jaffray, RBC Capital Markets, and Thomas Weisel Partners.

Read More »

IPO FILING: Fluidigm (FLDM)

Fluidigm, a California-based life science research device provider, has filed with the SEC to become public this morning. The offering shows a total proposed maximum aggregate price of $86,250,000. They applied to trade on the Nasdaq Global Market under the ticker “FLDM.” The book-running managers are listed as Morgan Stanley, UBS Investment Bank, and Leerink Swann.

Fluidigm develops and manufactures their proprietary Integrated Fluidic Circuit system that improves the productivity in life science research by allowing researches to perform thousands of precise biochemical measurements on very small amounts of matter. They believe their product has the flexibility to be used in a variety of science sectors and overcomes other existing microwell-based systems.

The company posted product revenues of $3.9 million and $4.4 million in 2006 and 2007, respectively. However, due to high production, research and development, and other expenses, the company showed net losses of $23.5 and $25.4 in 2006 and 2006, respectively. 

You can join our open email distribution list to hear about IPO’s, special financings, secondary offerings, M&A, and more previews for other special situations in various stages.

Rachel Lopez
April 14, 2008

Agria, A Suit & A Dismal IPO (GRO)

Chinese-based agriculture solutions provider, Agria Corp. (NYSE: GRO) issued a statement this morning noting that the company will strongly defend itself against the class action suit filed against them for alleged violations of the S.E.C. Securities Act of 1933.

The complaint filed by the law firm of Schiffrin Barroway Topaz and Kessler alleges that the company did not disclose pertinent information during their IPO in November of 2007. Specifically, the suit alleges that company failed to disclose negotiations being conducted with the COO and other executives for compensation packages and this led to financial statements after the IPO that were not analogous to those filed in the prospectus.

As stated above, Agria plans to vigorously defend itself against any and all allegations of this nature. Whether or not the company violated rules is still an outstanding, but the dismal post-IPO is so bad you’d think the company has been sued every day of its operations.

Shares are down over 8% in early morning trading to $4.35. The 52-week range is $4.03 to $17.00. The company’s IPO share price was $16.50.  When you see performance like this, the initial assumption is that maybe the company should have never been public at all.  When you take into consideration that it has agriculture and China in it, then you really have to wonder why it has failed so horribly.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Jon C. Ogg
April 14, 2008

Jon Ogg produces the Special Situation Investing Newsletter.  He can be reached at jonogg@247wallst.com and he does not own securities in the companies he covers.

Wachovia Financing Terms Less Dilutive Than Others (WB)

Wachovia Corporation (NYSE: WB) has priced its offerings for common stock and convertible preferred stock right before the open this Monday after a dismal earnings report.

They plan to offer 145,833,334 shares of common stock for $3.5 billion. They are also offering 3,500,000 shares of Non-Cumulative Perpetual Convertible Class A preferred stock, Series L, for $3.5 billion and a liquidation preference of $1,000 per share. The two offerings are independent of the completion of the other and underwriters were granted 21,875,000 shares of additional common stock and 525,000 shares of convertible preferred stock in over-allotment options.

The actual pricing is at $24.00 per share, and if all overallotments are exercised Wachovia will realize some $3.9 Billion in capital raised.  Shares are down 8% at $25.55 in early morning trading, and its market cap before this dilution is still listed as being in excess of $50 Billion.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Jon C. Ogg
April 14, 2008

Jon Ogg produces the Special Situation Investing Newsletter.  He can be reached at jonogg@247wallst.com and he does not own securities in the companies he covers.

Trina Solar, Profitability Over Internal Expansion (TSL)

Trina Solar Ltd. (NYSE: TSL) is halting the development of a previously announced polysilicon production facility, which originally had a total estimated cost of some $1 Billion.  Less than two weeks ago, the company announced it had secured long-term supply pacts over an 8-year period.

The solar photovoltaic products maker in China said its related equipment supply contract with a unit of GT Solar International Inc. will lapse as a result of this capacity not coming on-line.  This strategic decision came after what the company called a careful assessment of raw material requirements, along with recent and favorable long-term polysilicon market and supply condition developments.

Trina Solar’s stock closed on Friday at $38.00, and shares are indicated up about 3% between $39.25 and $39.50 in early pre-market trading this morning.  Its market cap is close to $950 million and the company is currently profitable.  Its 52-week trading range is $25.88 to $73.06.

At first this sounds cautionary in that the added capacity won’t be there.  But the shares indicating higher on the news as this implies more rewards for profitability monitoring rather than just capacity expansion  now that it secured longer-term pacts.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Jon C. Ogg
April 11, 2008

Jon Ogg produces the Special Situation Investing Newsletter.  He can be reached at jonogg@247wallst.com and he does not own securities in the companies he covers.

Goldman Sachs Dumps GE for Lockheed (LMT, GE)

This morning, Goldman Sachs has made a key call to its industrials sector.  It is adding Lockheed Martin (NYSE: LMT) to its Industrials Favorite Value List.  Goldman Sachs notes the nature of defense stocks versus industrials in a recession, expectations for a solid earnings report next week, current prices representing a solid entry point.  The firm also believes that Lockheed martin is the cheapest of the large cap defense stocks, and its $122 target implies a 20% upside in the stock at current levels.

While removing General Electric Co. (NYSE: GE) from this list is post-event, it’s really hard to argue with the level of disappointment and game-changer that its earnings miss and earnings warning posed on Friday.  GE is noted as pointing to soft healthcare equipment spending as well.

We noted this on our "Top 10 Pre-Market Calls" as well, but General Electric was downgraded to Perform from Outperform at Oppenheimer it was also downgraded to Peer Perform from outperform at Bear Stearns.

Jon C. Ogg
April 14, 2008

Top 10 Pre-Market Analyst Calls (ABB, CAH, EV, FAST, GE, MMC, PETM, SPW, V)

These are not the only analyst calls being seen this Monday in pre-market hours, but these are the top calls that 247WallSt.com is focusing on so far this morning:

  • ABB (NYSE: ABB) cut to Equalweight From Overweight at Lehman.
  • Cardinal Health (NYSE: CAH) removed from Conviction Buy List but maintained Buy at Goldman Sachs.
  • Eaton Vance (NYSE: EV) Raised to Neutral from Underweight at JPMorgan.
  • Fastenal (NASDAQ: FAST) Cut to Neutral from Buy at Piper Jaffray.
  • General Electric (NYSE: GE) downgraded to Perform from Outperform at Oppenheimer; cut to Peer Perform from outperform at Bear Stearns.
  • Marsh & McLennan (NYSE: MMC) Raised to Outperform at KBW.
  • PETsMART (NASDAQ: PETM) raised to Buy from Neutral at Banc of America.
  • SPX Corp (NYSE: SPW) cut to Hold at Deutsche Bank.
  • Visa (NYSE: V) started as Outperform at KBW.

Jon C. Ogg
April 14, 2008

A Big Loss At Wachovia (WB)

According to Reuters, the net loss for Wachovia (NYSE: WB) was $350 million. The loss available to common stockholders, including preferred stock dividends, was $393 million, or 20 cents per share, compared with a year-earlier profit of $2.3 billion, or $1.20 per share.

Wachovia also said it would reduce its quarterly dividend 41 percent to 37.5 cents per share from 64 cents.

And, of course, the bank will raise money by floating a preferred.

The shares should be bloodied today.

Douglas A. McIntyre

If Food Prices Are The World’s Greatest Economic Problem, There Is No Solution

At recent G-7 finance minister meetings and the IMF gathering, food prices were identified, by many measures,  as being a larger issue for the global economy than the credit crisis which is doing so much damage to financial market liquidity.

According to The Wall Street Journal "Surging commodity prices have pushed up global food prices 83% in the past three years, according to the World Bank — putting huge stress on some of the world’s poorest nations." And, that does not take into account what the phenomenon is doing to inflation rates in large countries including China and the US.

Feeding the starving sits way higher on the set of priorities for food supply than inflation does, but solving the two problems is related in almost all ways, and, it defies resolution in almost every way.

There are, at least, possible solutions to the rising price of oil. OPEC may see that its actions are gutting the GDP growth of many nations and decide that its is their own best interest not to see the global financial ecosystem come apart at the seams. The US could let out some of the petrol in the strategic oil reserves. The action, by itself, might push down speculation in oil and bring crude down by several dollars.

The credit issues plaguing banks and seizing up the credit markets has the potential, at least, of being resolved over the next year by central banks pumping capital into the system.

Food supply and demand has no central system for driving a resolution, no central banks or oil cartel.

Many of the world’s leaders believe the US is at fault for much of the food shortage. They reason that selling crops for biofuels is a profitable but cruel use of a commodity which is in short supply. There is some truth in the finger pointing, but it is not the whole truth.

Crop yield in large agricultural economies like the US, Canada, and Russia is at an all-time peak, Better land management, fertilizer, and seed have seen to that. But, the sad fact is that the number of the world’s poor and under-nourished grows with the global population increase and war pushes more and more people off of producing land and into huge refuge camps which produce no crops by have an unusually immediate need for food.

With food production worldwide running at levels which are unlikely to rise and the number of people who need food immediately for survival moving up, there is no ready solution to bringing down the inflation rate of agricultural commodities.

Unless and until the central banks are willing to underwrite the cost of food by purchasing commodities and selling them below market nothing will happen. They have taken bad paper from banks in exchange for good cash. Some counties, like China, already underwrite the cost of fuel to keep their economies growing.

Bring down food prices involves buying up the fruits of the global farming system and "loaning" it to many of the world’s nations. But, who has a check-book that large?

Douglas A. McIntyre

Deutsche Bank (DB) Has A Deal For You

Deutsche Bank (NYSE: DB) is in the process of selling $20 billion of LBO loans. If the financial firm thought its earnings were OK and that its balance sheet would allow it to do business as usual going forward, it is not likely that it would be in the market for buyers.

In all likelihood Deutsche Bank will have to take the kind of haircut that Citigroup (C) took last week when the company said it would sell $12 billion of corporate leveraged paper to private equity firms. Citi will even loan them some of the money for the purchases.

Many Wall Street experts think that the fact that these loans sell at all is a sign that the market is becoming more liquid and will open up to more and more transactions which will help troubled financial companies get bad assets off of their balance sheets. That may be true. Gamblers at private equity firms may be out in force betting that they can buy paper at $.90 on the dollar and ride its value up as the economy gets better. But, that is only a series of transactions for corporate bonds

None of that addresses whether the swaps market could face a crisis or whether the $4 trillion in home equity ARMs will start to show cracks and major default rates. It does not address the write-downs coming in consumer credit and car loans. It will also not be likely to offset further write-downs in mortgage instruments if subprime homeowners continue to go through foreclosures.

Selling leveraged corporate debt is a sign that the market has found some liquidly, but it is not a sign that problems are over. The size of the future peril is likely to be greater than what is already in the past.

Douglas A. McIntyre

Wachovia (WB) Deal Shows Banks Still In Peril

Wachovia (NYSE: WB) will raise between $6 billion and $7 billion. Will the money come in at $28 where the bank trades now? That is already down by half from the 52-week high of almost $57. What a deal that would be.

But, no, the new financing will be at the take-under price of as little as $23.

Wachovia has moved its earnings release up to today, a sure sign of news, big news. The Wall Street Journal writes "According to people familiar with the situation, Wachovia’s deal is similar in structure to the $7 billion infusion announced by Washington Mutual Inc. last week" In other words it is a mess that undermines the stock value of current shareholders.

Wachovia did make its life worse by buying Golden West which had many of its loans in the troubled California market. But, the need for capital is also a sign that Q1 earnings at most banks could be worse than expected. All of the major money centers and brokerages have exposure to the real estate market through mortgage-backed paper. Even GE (GE) could not avoid the pain of the current financial crisis. Citicorp (B) and Deutsche Bank (DB) are selling LBO loans at a discount to help their balance sheets

Wachovia may be reporting earlier than most large financial firms, but its numbers are likely to tell Wall Street that the crisis in the credit markets is far from over. The omens of trouble are back in the atmosphere.

Douglas A. McIntyre

Delta (DAL) And Northwest (NWA): A Day Late And A Dollar Short

The revived merger between Delta (DAL) and Northwest (NWA) is based on the premise that, in a airline industry depression, two carriers mashed together work better than if they remained independent. It is an argument which is half again too clever but has no merit to speak of.

According to The Wall Street Journal "The deal could value Northwest at roughly $3 billion, these people said, though terms were still being negotiated. That would be well below Northwest’s market value of more than $4.6 billion as of Feb. 1, reflecting the industry’s worsening prospects in recent weeks." The airline industry has been keelhauled to the extend that United (UAUA), Northwest, and Delta have lost over 30% of their market caps in three months.

The two significant stimulations for airline mergers now are rising fuel prices and a likely sharp drop in passenger demand as the economy slows. Since a merger will not be effective finished for several months, neither of these is addressed in the short-term.

The more painful reality of the possible transaction is that it solves neither fuel prices nor passenger revenue-based troubles. It may allow for some elimination of duplicate routes and some employees. But, airline pilots have not approved the merger and a strike by them could cost the new company tens of millions of dollars be shutting the operation down. Scabs are hard to find when they have to replace people with twenty years of training.

Merging Northwest and Delta is playing chess while the house is on fire. Better to stay separate and avoid the migraine of integrating reservations and IT systems which usually POs customers to no end.

Negotiating with unions, hedging fuel and cutting routes does not require the expenses and risks of a merger.

Douglas A. McIntyre